Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly in the obesity drug space.
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly in the obesity drug space.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
